A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma

Summary

The prognosis of patients with recurrent, late-stage inoperable, or progressed biliary tract carcinoma (BTC) is generally poor. The goal of this clinical study is to determine the effectiveness and safety of abemaciclib in patients with late-stage or progressed BTC that has failed one line of chemotherapy.

Timeline

Start

2021-09-24

Primary completion

2023-08-15

Completion

2023-08-15

Outcome

Outcome not reported

Stopped (Business): “The manufacturer and funder Eli Lilly requested to terminate the study”

Drugs

Indications